loading...

Dysmenorrhea Daily Diary (DysDD )

Nguyen AM; Kitchen H; Rehman T; Humphrey L; Norquist JM

Distributed by Mapi Research Trust

ProQolid

Distributed by Mapi Research Trust

Basic description

  • Published in 2015
  • The DysDD is a diary and need to be administered daily 
Authors

Nguyen AM; Kitchen H; Rehman T; Humphrey L; Norquist JM

Copyright
Copyright © (2020) Merck & Co., Inc., Kenilworth, NJ, USA and its affiliates. All rights reserved.
Objective
To assess menstrual bleeding, pelvic pain, use of rescue medication, and impact of pelvic pain/camps on the daily life of patients with dysmenorrhea
Therapeutic area
  • Pathological Conditions, Signs and Symptoms
Therapeutic indication

Dysmenorrhea

Type of Clinical Outcome Assessment (COA)
  • pro PRO
Original language(s)
  • English for the USA
Bibliographic reference(s) of the original questionnaire

Nguyen AM, Humphrey L, Kitchen H. A qualitative study to develop a patient-reported outcome for dysmenorrhea. Qual Life Res. 2015 Jan;24(1):181-91. (Full Text Article)

Nguyen AM, Arbuckle R, Korver T. Psychometric validation of the dysmenorrhea daily diary (DysDD): a patient-reported outcome for dysmenorrhea. Qual Life Res. 2017 Aug;26(8):2041-2055. (PubMed Abstract)

Access this questionnaire

All requests have to be submitted through our online request management:

  1. Log in or Register for free
  2. Submit your request (Tutorials are available on our FAQs)
  3. Our PROVIDE team will get back to you with the needed information and license agreement in a timely manner.

Fees may apply to your project.

The copyright owner, Merck, receives no compensation for granting license to use the COA and its translations.


Contact and conditions of use

Authors

Nguyen AM; Kitchen H; Rehman T; Humphrey L; Norquist JM

Contact information

Mapi Research Trust
PROVIDE™
27 rue de la Villette
69003 Lyon
France
Phone: +33 (0)4 72 13 66 66

Conditions of use

All requests have to be submitted through our online request management:

  1. Log in or Register for free
  2. Submit your request (Tutorials are available on our FAQs)
  3. Our PROVIDE team will get back to you with the needed information and license agreement in a timely manner.

Fees may apply to your project.

The copyright owner, Merck, receives no compensation for granting license to use the COA and its translations.

Review copy

Examination copies can only be used for the limited purpose of examining the suitability of the Questionnaire for subsequent research and/or clinical use, and cannot be used in research or in clinical practice or distributed to others.
You are not authorized to modify, retype, translate, copy or otherwise duplicate the Questionnaire except with the further and prior written permission of Mapi Research Trust / the developers / copyright holders / distributors.

Languages

Original language(s)

  • English for the USA

Translations

The list of available translations is subject to constant changes and may not be exhaustive. It is provided for information only. Some recently produced translations may not be included in the list below yet. Please do check the status of available translations with Mapi Research Trust / the developers / copyright holders / distributors.

Also, the listed translations may not have undergone a full linguistic validation process and may require further work to be suitable for use in a study.

No translation

Conditions to translate

Recommended vendor for translation work: Mapi/ICON Language Services

Academic Translation

If you wish to translate the questionnaire:

  1. Log in or Register for free
  2. Submit your request for translation online (Tutorials are available on our FAQs)
  3. Our PROVIDE team will send you a translation agreement along with Linguistic Validation Guidelines.

More information on translations

For information on, or permission to use the translations, please contact Mapi Research Trust

Member Access

Subscribe to PROQOLID to access to full information

Access to advanced descriptions of Clinical Outcome Assessments (COAs)

A question? Contact us